Botensilimab/balstilimab data in neoadjuvant colorectal cancer selected for asco-gi 2024

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that data from an investigator sponsored trial (ist) evaluating botensilimab (bot, multifunctional ctla-4 immune activator) in combination with balstilimab (bal, pd-1 antibody) in neoadjuvant colorectal cancer (crc) will be presented at the upcoming asco-gi meeting, to be held january 18 – 20, 2024 in san francisco,.
AGEN Ratings Summary
AGEN Quant Ranking